Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

NCT04308395 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

108

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated early due to low blinded event rate and this study termination is not related to safety of the drug Patidegib Topical Gel, 2%.

Conditions

Basal Cell Nevus Syndrome

Interventions

DRUG: Patidegib Topical Gel, 2%

Sponsor

Sol-Gel Technologies, Ltd.